Measure Title: USE OF LONG-TERM CONTROL DRUGS FOR PERSISTENT ASTHMA

Disease State: Asthma

Strength of Recommendation: A - B

Physician Specialties: Allergy, Family Practice, Gerontology, Internal Medicine, Pediatric Pulmonology, Pediatrics

Clinical Rationale

- Approximately 30.8 million persons in the United States have been diagnosed with asthma.[1]  
- In 2002, asthma led to over 1.9 million emergency department visits, about 500,000 hospitalizations, and over 4000 deaths. [1]

Reason for Indicated Intervention or Treatment

- Regular use of inhaled corticosteroids improves asthma control, decreases hospital admissions, and mortality from asthma in adults and children with persistent asthma.[2-4]  
- For patients with moderate persistent asthma, adding a long-acting beta-2 agonist to a low or medium dose inhaled corticosteroid improves lung function and symptoms, decreases asthma exacerbations, and reduces the use of additional short-acting beta-2-agonists.[4]  
- Many patients with persistent asthma are still being under-treated with long-term control medications.[5-7]

Evidence supporting Intervention or Treatment

- Randomized, controlled trials have shown that inhaled corticosteroid use in patients with persistent asthma, when compared to placebo or beta-2-agonists, results in improved pre-brochodilator FEV1, reduced oral steroid and supplemental short-acting beta-2-agonist use, and decreased airway responsiveness, asthma symptom scores, and hospitalizations.[8-23]  
- Results from randomized, controlled trials on using leukotriene modifiers alone for those with persistent asthma are mixed. Some randomized control trials show no difference between leukotriene modifier and inhaled corticosteroid use [24-28], but others found increased asthma exacerbations and poorer symptom control in those using the leukotriene modifiers.[29-31]  
- For asthma that is poorly controlled with inhaled corticosteroid use alone, randomized controlled trials have shown that patients have better symptom control when long-acting beta-2-agonists are added, instead of leukotriene modifiers.[32-34]  
- Most randomized control trials demonstrate that adding a long-acting beta-2-agonist to an inhaled corticosteroid decreases asthma exacerbations more than increasing the inhaled corticosteroid dose.[35-38] However, one randomized control trial found that increasing the inhaled corticosteroid dose led to better symptom control than adding a long-acting beta-2-agonist.[39]

Clinical Recommendations

- An expert panel convened by the National Heart, Lung and Blood
Institute, the National Asthma Education and Prevention Program (NAEPP), developed Guidelines for the Diagnosis and Management of Asthma. The NAEPP's 2002 update recommends inhaled corticosteroids as first-line therapy in all patients older than 5 years with persistent asthma.[4]

- Other long-term medications such as leukotriene modifiers, cromolyn, nedocromil and theophylline are now considered to be second-line or alternative treatments.[4]
- For patients poorly controlled with inhaled corticosteroid use, the NAEPP recommends the addition of a beta-2-agonist over the addition of a leukotriene modifier.[4]

The Joint Council of Allergy, Asthma and Immunology (JCAAI) recommends the use of β2 agonists, theophylline, cromolyn, nedocromil, and inhaled corticosteroids for the pharmacotherapeutic treatment of chronic asthma.[40]

Source

Health Plan Employer Data and Information Set (HEDIS®) 2006 Technical Specification

Denominator

Continuously enrolled members ages 5 - 56 years with evidence of persistent asthma (mild to severe) during the measurement year and the year prior to the measurement year.

Denominator Exclusion

Members without prescription benefits or who were diagnosed with emphysema or chronic obstructive pulmonary disease (COPD) any time prior to the end of the measurement year.

Numerator

Members who received a prescription for a medication appropriate for long-term control of asthma during the measurement year.

Interpretation of Score

High score implies better performance

Physician Attribution

Score all physicians (in the selected specialties) who saw the member during the reporting period.

External Files Required for Analysis

Denominator file name: asmod_den_medlist_2006.xls
Numerator file name: asmod_num_medlist_2006.xls
Source: NCQA website
Updated Annually

References

1 **Indicator Classification** (Adapted from Health Plan Employer Data Information Set (HEDIS®) technical specifications)

- **Diagnosis**
  Measures applicable to patients receiving diagnostic workups for a symptom or condition that delineate appropriate laboratory or radiological testing to be performed (e.g. evaluation of thyroid nodule; pregnancy test in patients with vaginal bleeding or abdominal pain)

- **Effectiveness of Care**
  - **Prevention**
    Measures applicable to asymptomatic individuals that are designed to prevent the onset of the targeted condition (e.g. immunizations).
  - **Screening**
    Measures applicable to asymptomatic patients who have risk factors or pre-clinical disease, but in whom the condition has not become clinically apparent (e.g. pap smears; screening for elevated blood pressure).
  - **Disease Management**
    Measures applicable to individuals diagnosed with a condition that are part of the treatment or management of the condition (e.g. cholesterol reduction in patients with diabetes; radiation therapy following breast conserving surgery; appropriate follow-up after acute event).
  - **Medication Monitoring**
    Measures applicable to patients taking medications with narrow therapeutic windows and / or potential preventable significant side effects or adverse reactions (e.g. thyroid stimulating hormone (TSH) testing after levothyroxine dose change; hepatic enzyme monitoring for patients using antimycotic pharmacotherapy)
  - **Medication Adherence**
    Measures applicable to patients taking medications for chronic conditions that are designed to assess patient adherence to medication (e.g. adherence to lipid lowering medication).
  - **Utilization**
    Measures applicable to patients receiving treatment for a symptom or condition that advocate appropriate utilization of laboratory and pharmaceutical resources (e.g. conservative use of imaging for low back pain; inappropriate use of antibiotics for viral upper respiratory infection).
2 Strength of Recommendation

Strength of Recommendation Based on a Body of Evidence

FIGURE 2. Algorithm for determining the strength of a recommendation based on a body of evidence (applies to clinical recommendations regarding diagnosis, treatment, prevention, or screening). While this algorithm provides a general guideline, authors and editors may adjust the strength of recommendation based on the benefits, harms, and costs of the intervention being recommended. (USPSTF = U.S. Preventive Services Task Force)